XenoGesis is a laboratory-based contract research organisation specialised in pre-clinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling & simulation for human PK and dose prediction. The core XenoGesis team has a proven track record of delivery in drug discovery, and works with clients through to development and the clinic.
Through a consultative approach, XenoGesis helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for clients. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis. The organisation combines its state-of-the-art in vitro, in vivo and bioanalytical capabilities with its expert pharmacokinetic/ pharmacodynamic (PK/PD) data interpretation services.
